ImmunoScape Raises $14M to Facilitate the Discovery and Characterization of Cancer-Specific T-cell Receptors
Summary
SAN DIEGO & SINGAPORE--(BUSINESS WIRE)-- ImmunoScape, a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR-T-cell therapeutics today announced that it has raised $14M in new financing. We are especially delighted that Amgen Ventures has become an investor and we look forward to working with their team to address important unmet medical needs with ImmunoScapes technology.Amgen invests in promising new solutions to address healthcares biggest challenges, especially those that offer unique, value-based approaches that align with our mission to serve patients fighting serious illness, said Philip Tagari, vice president of research (therapeutic discovery), Amgen. We are excited to work with their team to unlock the full power of this technology.With research laboratories in both San Diego and Singapore, ImmunoScape is one of the global pioneers of TCR discovery. From their origins at Singapores Agency for Science, Technology, and Research (A*Star), the companys global team of immunologists are pursuing major breakthroughs in TCR cell therapy. The companys proprietary Deep Immunomics technology and machine learning platforms enable highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors.